Mersana Therapeutics

Adimab, Mersana form antibody-drug conjugate alliance

Wednesday, August 1, 2012 01:49 PM

Adimab, a Lebanon, N.H.-based technology company focused on fully human therapeutic antibodies, and Mersana Therapeutics, a next-generation antibody-drug conjugate (ADC) company based in Cambridge, Mass., have joined forces to offer integrated antibody discovery and ADC technologies.

More... »


Mersana raises $27M to advance Fleximer antibody-drug conjugates

Wednesday, August 1, 2012 11:34 AM

Mersana Therapeutics, a Cambridge, Mass.-based biopharmaceutical company developing Fleximer antibody-drug conjugate (ADC) platform, has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA).

More... »


Mersana Therapeutics appoints Michael A. Metzger as executive VP, COO

Wednesday, April 20, 2011 11:46 AM

Michael A. Metzger has joined Mersana Therapeutics, a platform-based cancer therapeutics company, as executive vice president & chief operating officer. 

More... »

Mersana initiates phase Ib of lead cancer drug

Tuesday, March 29, 2011 12:54 PM

Massachusetts-based Mersana Therapeutics announced the initiation of a phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer.  The study will be carried out in 10 clinical centers in the U.S. 

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs